Notably, many studies have demonstrated that abnormal ID1 expression is strongly correlated with hematologic disorders, including myeloproliferative neoplasms (MPNs), multiple myeloma (MM), and myeloid and lymphoblastic leukemia, positioning it as a potent prognostic biomarker and a viable therapeutic target [19–22]. The gene discussed is ID1; the disease is Miyoshi myopathy.